Fosun Pharma Announces First Participant Dosed in China Phase 1 Trial of FXB0871, an Innovative Immuno-oncology Therapy
May 29, 2026 16:30
CST Updated
May 30, 02:04
Fosun Pharmaceutical
Healthcare Industry Group